Exciting news! 🎉 Qwark’s AI pharmacy assistant (in beta) is now live and ready to answer any medication-related questions you may have!Try it out now!
  1. Drugs
  2. Delstrigo
Delstrigo Image

Delstrigo

Free shipping
No membership fee
Qwark price promise
Qwark is committed to lowering your prescription prices. We will always recommend the best price we can find. If you find a lower price on an identical, in-stock product, tell us and we'll match it.

For more strengths and prices, please contact Qwark support

Need help?

Our patient support team is available Monday through Friday 8AM - 6PM PST, and Saturday 9AM - 12PM PST.

What Is Delstrigo?

Delstrigo is a branded prescription medication for the treatment of human immunodeficiency virus (HIV) infection. It is a combination drug that contains three active ingredients: doravirine, lamivudine, and tenofovir disoproxil fumarate. Doravirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that helps to inhibit the replication of the HIV virus by blocking the viral enzyme reverse transcriptase. Lamivudine and tenofovir disoproxil fumarate are nucleoside reverse transcriptase inhibitors (NRTIs) that also work to prevent the virus from multiplying in the body. By combining these three medications, Delstrigo helps to control the underlying viral infection and slow down the progression of HIV/AIDS. It is important to note that Delstrigo is not a cure for HIV/AIDS, but rather it is used to manage the condition and reduce the viral load in the body, thereby improving the immune system and reducing the risk of developing AIDS-related complications. Delstrigo is available only by prescription and should be taken as directed by a healthcare professional. It is crucial to adhere to the prescribed dosing schedule and continue with regular monitoring and follow-up with a healthcare provider while using this medication. Additionally, it is important to note that Delstrigo does not protect against other sexually transmitted infections, so safer sex practices should still be followed.

How to use Delstrigo?

Delstrigo is a brand-name prescription drug that is used to control the underlying viral infection that causes HIV/AIDS. This medication is a combination of three different drugs: doravirine, lamivudine, and tenofovir disoproxil fumarate. When taking Delstrigo, it is important to follow your doctor's instructions and the dosing regimen that is prescribed to you. Typically, this medication is taken once a day, with or without food. It's important to take it consistently at the same time each day to maintain steady levels of the drug in your system. The tablets should be swallowed whole and not crushed, chewed, or split. If you have difficulty swallowing tablets, talk to your doctor or pharmacist for possible alternatives. It's crucial to note that Delstrigo is not a cure for HIV/AIDS. It is an antiretroviral medication that helps to control the virus and prevent it from multiplying in the body. It is meant to be used in combination with other HIV medications as part of a comprehensive treatment plan. If you have any questions or concerns about how to use Delstrigo, it is important to consult with your healthcare provider for personalized guidance. They will provide you with the specific instructions tailored to your condition and needs.

There are several important warnings associated with the use of Delstrigo, a combination drug used to treat HIV/AIDS. It is crucial to be aware of these warnings to ensure safe and effective use of the medication. 1. Severe Skin and Hypersensitivity Reactions: Delstrigo may cause serious and potentially life-threatening skin reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis. These reactions can lead to severe skin rashes, blistering, and peeling. Additionally, hypersensitivity reactions (allergic reactions) have been reported with Delstrigo use. If you experience any signs of these reactions, such as skin rash, fever, or facial swelling, seek immediate medical attention. 2. Lactic Acidosis and Severe Hepatomegaly: Lactic acidosis, a condition characterized by the buildup of lactic acid in the body, and severe hepatomegaly (enlargement of the liver) have been reported with the use of nucleoside analogs, a component of Delstrigo. Inform your healthcare provider if you experience symptoms such as fatigue, muscle pain, abdominal discomfort, or yellowing of the skin or eyes. 3. Worsening of Hepatitis B Infection: Delstrigo is not approved for the treatment of hepatitis B virus (HBV) infection. If you have both HIV and HBV, the abrupt discontinuation of Delstrigo may lead to the worsening of your HBV infection. It is crucial to discuss any existing HBV infection with your healthcare provider. 4. Drug Interactions: Delstrigo can interact with other medications, including those used for the treatment of HIV/AIDS. Some drug combinations can increase the risk of side effects or reduce the effectiveness of one or both drugs. Inform your doctor about all the medications, supplements, and herbal products you are taking to avoid potential interactions. 5. Immune Reconstitution Syndrome: In some HIV-infected patients, immune system recovery may trigger inflammation in previously treated infections (such as opportunistic infections) or autoimmune disorders. It is important to promptly inform your healthcare provider of any new symptoms or changes in existing conditions. Remember, this is not an exhaustive list of warnings associated with Delstrigo. It is essential to consult with your healthcare provider or refer to the medication's package insert for a comprehensive understanding of the potential risks and precautions associated with its use.

Before taking Delstrigo, it is important to consider the following warnings and precautions: 1. HIV Resistance: Delstrigo is specifically designed to treat HIV infections in individuals who have not previously received antiretroviral therapy or those who have no history of known HIV mutations associated with resistance to any of its three components (doravirine, lamivudine, and tenofovir disoproxil fumarate). Resistance testing should be conducted before starting Delstrigo to ensure its effectiveness. 2. Hepatitis B Coinfection: Delstrigo is not recommended as the sole treatment for individuals with HIV and hepatitis B virus (HBV) coinfection. Before initiating treatment, it is crucial to assess the patient's HBV status. If HIV and HBV coinfection is present, specific treatment guidelines for both infections should be followed. 3. Renal Impairment: Delstrigo contains tenofovir disoproxil fumarate, which can cause renal toxicity and impaired kidney function. Prior to starting treatment, the patient's renal function should be evaluated. Regular monitoring of renal function is also recommended during therapy. 4. Lactic Acidosis/Severe Hepatomegaly: Rare cases of lactic acidosis (buildup of lactic acid in the blood) and severe hepatomegaly (enlarged liver) have been reported with the use of nucleoside analogues, including lamivudine and tenofovir disoproxil fumarate. Symptoms may include unusual tiredness, muscle pain, respiratory distress, and stomach discomfort. If these symptoms occur, immediate medical attention should be sought. 5. Immune Reconstitution Syndrome: In HIV-infected individuals, immune reconstitution syndrome may occur when antiretroviral therapy is started. This syndrome is characterized by the sudden onset of inflammatory reactions to preexisting opportunistic infections, which may require additional treatment. It is essential to consult with a healthcare provider before using Delstrigo to discuss individual medical history, potential interactions, and any other concerns related to this medication. Adhering to the prescribed dosage and following healthcare provider instructions is crucial for safe and effective use.

Some common side effects of Delstrigo (doravirine/lamivudine/tenofovir disoproxil fumarate) may include headache, nausea, diarrhea, fatigue, and abnormal dreams. These side effects are usually mild and tend to improve over time as the body adjusts to the medication. Less common but more serious side effects can occur as well. These may include allergic reactions, liver problems, lactic acidosis (a buildup of lactic acid in the blood), and an increased risk of developing infections. It is important to seek medical attention if you experience any severe or persistent side effects while taking Delstrigo. It's worth noting that this is not an exhaustive list of side effects, and individual experiences may vary. It is always advisable to consult with a healthcare professional for more detailed information about potential side effects associated with Delstrigo and to discuss any concerns you may have.

Delstrigo is a brand-name prescription medication that is used to treat HIV-1 infection in adults who have not received prior antiretroviral therapy, or who have had a well-controlled viral load on their current antiretroviral regimen for at least 6 months and are not known to have any history of HIV treatment failure. Delstrigo is a combination drug that contains three active ingredients: 1. Doravirine: It is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that works by inhibiting the reverse transcriptase enzyme, which is necessary for the replication of the HIV virus. 2. Lamivudine: Lamivudine is a nucleoside reverse transcriptase inhibitor (NRTI) that also works by inhibiting the reverse transcriptase enzyme. 3. Tenofovir disoproxil fumarate: This drug belongs to a class of medications known as nucleotide reverse transcriptase inhibitors (NtRTIs) and also works by inhibiting the reverse transcriptase enzyme. These three active ingredients work together to suppress the replication of the HIV virus and control the viral load in the body. It is essential to take Delstrigo as prescribed by a healthcare professional and adhere to the recommended dosages for optimal treatment outcomes.

Delstrigo, a brand-name combination drug used to manage HIV/AIDS, should be stored properly to maintain its effectiveness and safety. Here are some guidelines for handling its storage: 1. Temperature: Store Delstrigo at room temperature, typically around 20-25 degrees Celsius (68-77 degrees Fahrenheit). Avoid extreme temperatures and do not freeze the medication. 2. Moisture: Keep the medication away from excessive moisture, as it can affect its stability. Store it in a dry place, preferably in its original packaging and container. 3. Sunlight: Protect Delstrigo from direct sunlight and prolonged exposure to light, as it may degrade the medication. Store it in a dark place, such as a cabinet or drawer. 4. Childproof: Ensure that the medication is stored in a childproof container, out of reach of children and pets. This is important to prevent accidental ingestion. 5. Storage location: Choose a storage area that is secure and safe, where the medication will not be easily accessed by others. A cabinet or drawer that can be locked or kept out of sight can be a suitable option. Always check the specific storage instructions provided by the manufacturer or on the medication packaging. If you have any doubts or concerns about proper storage, consult your healthcare provider or pharmacist for guidance.